Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis.
brain metastases
frailty
non-small cell lung cancer
outcome
overall survival
sarcopenia
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jul 2021
03 Jul 2021
Historique:
received:
06
06
2021
revised:
28
06
2021
accepted:
01
07
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
21
7
2021
Statut:
epublish
Résumé
Neurosurgical resection represents an important therapeutic pillar in patients with brain metastasis (BM). Such extended treatment modalities require preoperative assessment of patients' physical status to estimate individual treatment success. The aim of the present study was to analyze the predictive value of frailty and sarcopenia as assessment tools for physiological integrity in patients with non-small cell lung cancer (NSCLC) who had undergone surgery for BM. Between 2013 and 2018, 141 patients were surgically treated for BM from NSCLC at the authors' institution. The preoperative physical condition was assessed by the temporal muscle thickness (TMT) as a surrogate parameter for sarcopenia and the modified frailty index (mFI). For the ≥65 aged group, median overall survival (mOS) significantly differed between patients classified as 'frail' (mFI ≥ 0.27) and 'least and moderately frail' (mFI < 0.27) (15 months versus 11 months (
Identifiants
pubmed: 34283079
pii: cancers13133353
doi: 10.3390/cancers13133353
pmc: PMC8267959
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Neurosci. 2020 Nov;81:95-100
pubmed: 33222979
Front Physiol. 2017 Dec 12;8:1045
pubmed: 29311975
Neuro Oncol. 2019 Dec 17;21(12):1587-1594
pubmed: 31369680
Lung Cancer. 2020 May;143:19-26
pubmed: 32200137
Nat Rev Rheumatol. 2017 Jun;13(6):340-347
pubmed: 28469267
PLoS One. 2018 Nov 29;13(11):e0207849
pubmed: 30496307
Eur J Surg Oncol. 2019 May;45(5):728-735
pubmed: 30348603
J Neurooncol. 2018 Oct;140(1):173-178
pubmed: 30008154
J Neurooncol. 2020 Sep;149(3):421-427
pubmed: 32989681
Front Med (Lausanne). 2020 Nov 30;7:596270
pubmed: 33330560
Clin Med (Lond). 2016 Oct;16(5):455-458
pubmed: 27697810
J Neurooncol. 2020 Sep;149(3):455-461
pubmed: 32990861
J Clin Med. 2021 Feb 07;10(4):
pubmed: 33562331
Sci Rep. 2020 Jan 29;10(1):1456
pubmed: 31996766
J Cancer Res Clin Oncol. 2021 Mar;147(3):901-909
pubmed: 32929611
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Nat Rev Clin Oncol. 2019 Jun;16(6):341-355
pubmed: 30718843
Clin Geriatr Med. 2017 Aug;33(3):293-303
pubmed: 28689563
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142701
Thorac Cancer. 2021 Jun 13;:
pubmed: 34121347
J Clin Oncol. 2020 Nov 10;38(32):3773-3784
pubmed: 32931399
J Clin Med. 2021 Mar 25;10(7):
pubmed: 33806224
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Eur Radiol. 2017 Aug;27(8):3167-3173
pubmed: 28050694
Handb Clin Neurol. 2018;149:27-42
pubmed: 29307358
Cancers (Basel). 2021 Feb 02;13(3):
pubmed: 33540564
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
BMC Geriatr. 2016 Oct 5;16(1):170
pubmed: 27716195
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Maturitas. 2017 Feb;96:10-15
pubmed: 28041587